KR20150009540A - Pi-3 키나제 억제제에 대한 투여 요법 - Google Patents
Pi-3 키나제 억제제에 대한 투여 요법 Download PDFInfo
- Publication number
- KR20150009540A KR20150009540A KR1020147031775A KR20147031775A KR20150009540A KR 20150009540 A KR20150009540 A KR 20150009540A KR 1020147031775 A KR1020147031775 A KR 1020147031775A KR 20147031775 A KR20147031775 A KR 20147031775A KR 20150009540 A KR20150009540 A KR 20150009540A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- substituted
- formula
- compound
- pharmaceutically acceptable
- Prior art date
Links
- 0 CN(C(*)C(*)N(*)C1*)C1O Chemical compound CN(C(*)C(*)N(*)C1*)C1O 0.000 description 4
- ODRLCTONCNSRBQ-UHFFFAOYSA-N CC(C)(C)OC(N(CC(N1C)=O)CC1=O)=O Chemical compound CC(C)(C)OC(N(CC(N1C)=O)CC1=O)=O ODRLCTONCNSRBQ-UHFFFAOYSA-N 0.000 description 1
- CJDYFMIDIQXELO-UHFFFAOYSA-N CC(C)(C)OC(N1CCN(C)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(C)CC1)=O CJDYFMIDIQXELO-UHFFFAOYSA-N 0.000 description 1
- FOYROUKGPPBNAN-UHFFFAOYSA-N CC(C)(C)OC(NC(CCC(N1C)=O)C1=O)=O Chemical compound CC(C)(C)OC(NC(CCC(N1C)=O)C1=O)=O FOYROUKGPPBNAN-UHFFFAOYSA-N 0.000 description 1
- VDQFWSAIURVIGH-UHFFFAOYSA-N CC(NC(CO)C(N)=O)=O Chemical compound CC(NC(CO)C(N)=O)=O VDQFWSAIURVIGH-UHFFFAOYSA-N 0.000 description 1
- FLGCKPIDGVTCSU-UHFFFAOYSA-N CC(NCCN(C)C)=O Chemical compound CC(NCCN(C)C)=O FLGCKPIDGVTCSU-UHFFFAOYSA-N 0.000 description 1
- UZJLYRRDVFWSGA-UHFFFAOYSA-N CC(NCc1ccccc1)=O Chemical compound CC(NCc1ccccc1)=O UZJLYRRDVFWSGA-UHFFFAOYSA-N 0.000 description 1
- MZCVTBJXTMEQLJ-UHFFFAOYSA-N CC(NCc1ccncc1)=O Chemical compound CC(NCc1ccncc1)=O MZCVTBJXTMEQLJ-UHFFFAOYSA-N 0.000 description 1
- CLPZHEDSMNQBPP-UHFFFAOYSA-N CC1NC(C)CN(C)C1 Chemical compound CC1NC(C)CN(C)C1 CLPZHEDSMNQBPP-UHFFFAOYSA-N 0.000 description 1
- GYLDXXLJMRTVSS-UHFFFAOYSA-N CCCCNC(C)=O Chemical compound CCCCNC(C)=O GYLDXXLJMRTVSS-UHFFFAOYSA-N 0.000 description 1
- MIQPSMRKRPYFOB-UHFFFAOYSA-N CCN(CCO1)CC1/[O]=C1\N(C)CCCCC1 Chemical compound CCN(CCO1)CC1/[O]=C1\N(C)CCCCC1 MIQPSMRKRPYFOB-UHFFFAOYSA-N 0.000 description 1
- PREDVCVMQCMUDT-UHFFFAOYSA-N CN(C(CCC1N)=O)C1=O Chemical compound CN(C(CCC1N)=O)C1=O PREDVCVMQCMUDT-UHFFFAOYSA-N 0.000 description 1
- LAEXPJQUWCGDGC-UHFFFAOYSA-N CN(C(CNC1)=O)C1=O Chemical compound CN(C(CNC1)=O)C1=O LAEXPJQUWCGDGC-UHFFFAOYSA-N 0.000 description 1
- MKKLCSLYYDPKIX-UHFFFAOYSA-N CN(C(COC1)=O)C1=O Chemical compound CN(C(COC1)=O)C1=O MKKLCSLYYDPKIX-UHFFFAOYSA-N 0.000 description 1
- LNSWKKFCACLOPY-UHFFFAOYSA-N CN(C)C(CC(N1C)O)C1=O Chemical compound CN(C)C(CC(N1C)O)C1=O LNSWKKFCACLOPY-UHFFFAOYSA-N 0.000 description 1
- AGZLAKYFYNHCES-UHFFFAOYSA-N CN(CC(N1C)=O)CC1=O Chemical compound CN(CC(N1C)=O)CC1=O AGZLAKYFYNHCES-UHFFFAOYSA-N 0.000 description 1
- KYQVHILSCNSMGO-UHFFFAOYSA-N CN(CC1)CC1NC(OCc1ccccc1)=O Chemical compound CN(CC1)CC1NC(OCc1ccccc1)=O KYQVHILSCNSMGO-UHFFFAOYSA-N 0.000 description 1
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261647654P | 2012-05-16 | 2012-05-16 | |
US61/647,654 | 2012-05-16 | ||
PCT/US2013/040877 WO2013173283A1 (en) | 2012-05-16 | 2013-05-14 | Dosage regimen for a pi-3 kinase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20150009540A true KR20150009540A (ko) | 2015-01-26 |
Family
ID=48626588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020147031775A KR20150009540A (ko) | 2012-05-16 | 2013-05-14 | Pi-3 키나제 억제제에 대한 투여 요법 |
Country Status (19)
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX342326B (es) | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
ES2665619T3 (es) | 2013-03-14 | 2018-04-26 | Novartis Ag | 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante |
CN105979947A (zh) * | 2013-12-06 | 2016-09-28 | 诺华股份有限公司 | α-同工型选择性磷脂酰肌醇3-激酶抑制剂的剂量方案 |
WO2016109426A1 (en) * | 2014-12-29 | 2016-07-07 | Verastem, Inc. | Oral dosing regimen of a dual mtor and pi3 inhibitor |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
EP3370719A1 (en) * | 2015-11-02 | 2018-09-12 | Novartis AG | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
WO2018009895A1 (en) * | 2016-07-08 | 2018-01-11 | Autotelic Llc | Methods for trabedersen dosing by auc |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体 |
US4323581A (en) | 1978-07-31 | 1982-04-06 | Johnson & Johnson | Method of treating carcinogenesis |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
DE3752123T2 (de) | 1987-03-09 | 1998-05-14 | Kyowa Hakko Kogyo Kk | Derivate des physiologisch aktiven mittels k-252 |
US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
JP2766360B2 (ja) | 1988-02-04 | 1998-06-18 | 協和醗酵工業株式会社 | スタウロスポリン誘導体 |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
EP0540185A1 (en) | 1991-10-10 | 1993-05-05 | Schering Corporation | 4'-(N-substituted-N-oxide)staurosporine derivatives |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
EP0610433A1 (en) | 1991-11-08 | 1994-08-17 | The University Of Southern California | Compositions containing k-252 compounds for potentiation of neurotrophin activity |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5948898A (en) | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
US5621100A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
US5756494A (en) | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
WO1994005304A1 (en) | 1992-08-31 | 1994-03-17 | Ludwig Institute For Cancer Research | Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof |
DE69331228T4 (de) | 1992-09-21 | 2002-09-05 | Kyowa Hakko Kogyo Kk | Heilmittel für thrombozytopenia |
RO119721B1 (ro) | 1992-10-28 | 2005-02-28 | Genentech Inc. | Antagonişti ai factorului de creştere al celulelor vasculare endoteliale |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
AU681687B2 (en) | 1993-07-15 | 1997-09-04 | Minnesota Mining And Manufacturing Company | Imidazo(4,5-c)pyridin-4-amines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
EP0817627B1 (en) | 1993-12-23 | 2005-03-09 | Eli Lilly And Company | Protein kinase c inhibitors |
US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
WO1997007081A2 (en) | 1995-08-11 | 1997-02-27 | Yale University | Glycosylated indolocarbazole synthesis |
FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
DE69620445T2 (de) | 1995-12-08 | 2002-12-12 | Janssen Pharmaceutica Nv | (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren |
KR100447918B1 (ko) | 1996-07-25 | 2005-09-28 | 동아제약주식회사 | 대장을포함한위장관보호작용을갖는플라본및플라바논화합물 |
ATE309345T1 (de) | 1996-08-02 | 2005-11-15 | Genesense Technologies Inc | Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
AU744986B2 (en) | 1997-07-12 | 2002-03-07 | Cancer Research Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
US7348025B2 (en) | 1997-09-23 | 2008-03-25 | Research Development Foundation | Small particle liposome aerosols for delivery of anticancer drugs |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
CO5031249A1 (es) | 1998-05-29 | 2001-04-27 | Sugen Inc | Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas |
US20030083242A1 (en) | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
AU784045B2 (en) | 1999-06-25 | 2006-01-19 | Genentech Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
AU6014900A (en) | 1999-07-13 | 2001-01-30 | Kyowa Hakko Kogyo Co. Ltd. | Staurosporin derivatives |
MXPA02004366A (es) | 1999-11-05 | 2002-11-07 | Astrazeneca Ab | Derivados de quinazolina como inhibidores vegf. |
SK287142B6 (sk) | 2000-02-15 | 2010-01-07 | Sugen, Inc. | Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie |
AU2001253427B2 (en) | 2000-04-12 | 2007-02-08 | Genaera Corporation | A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group |
CZ300945B6 (cs) | 2000-06-30 | 2009-09-23 | Glaxo Group Limited | Zpusob prípravy 5-(6-chinazolinyl)-furan-2-karbaldehydu |
EP1650203B1 (en) | 2000-09-11 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Process of preparation of benzimidazol-2-yl quinolinone derivatives |
US6677450B2 (en) | 2000-10-06 | 2004-01-13 | Bristol-Myers Squibb Company | Topoisomerase inhibitors |
CA2434802C (en) | 2001-01-16 | 2013-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
WO2002062826A1 (fr) | 2001-02-07 | 2002-08-15 | Vadim Viktorovich Novikov | Procede de fabrication des peptides |
US20040186172A1 (en) | 2001-07-02 | 2004-09-23 | Houssam Ibrahim | Oxaliplatin active substance with a very low content of oxalic acid |
KR100484504B1 (ko) | 2001-09-18 | 2005-04-20 | 학교법인 포항공과대학교 | 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물 |
US20030134846A1 (en) | 2001-10-09 | 2003-07-17 | Schering Corporation | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors |
WO2003077902A1 (en) | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
US7071216B2 (en) | 2002-03-29 | 2006-07-04 | Chiron Corporation | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
US6900342B2 (en) | 2002-05-10 | 2005-05-31 | Dabur India Limited | Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof |
US6727272B1 (en) | 2002-07-15 | 2004-04-27 | Unitech Pharmaceuticals, Inc. | Leflunomide analogs for treating rheumatoid arthritis |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
EP1587473A4 (en) | 2002-12-27 | 2008-08-13 | Novartis Vaccines & Diagnostic | THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS |
US8193185B2 (en) | 2003-01-21 | 2012-06-05 | Novartis Vaccines And Diagnostics, Inc. | Use of tryptanthrin compounds for immune potentiation |
CA2520124A1 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of benzazole compounds for immunopotentiation |
US20050215795A1 (en) * | 2004-02-06 | 2005-09-29 | Bang-Chi Chen | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
CA2594713A1 (en) | 2005-01-26 | 2006-08-03 | Taiho Pharmaceutical Co., Ltd. | Anticancer drug containing .alpha.,.alpha.,.alpha.-trifluorothymidine and thymidine phosphorylase inhibitor |
EP1962839A4 (en) | 2005-11-14 | 2010-08-25 | Ariad Pharma Inc | ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER |
JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CA2922029C (en) | 2006-03-22 | 2017-11-28 | Medigene Ag | A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent |
PT2050749T (pt) | 2006-08-08 | 2018-01-02 | Chugai Pharmaceutical Co Ltd | Derivado de pirimidina como inibidador de pi3k e sua utilização |
US8222288B2 (en) * | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
EP2118087B1 (en) | 2007-02-06 | 2012-03-28 | Novartis AG | Pi 3-kinase inhibitors and methods of their use |
WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
EP2231147A2 (en) * | 2007-12-13 | 2010-09-29 | Novartis AG | Combinations of therapeutic agents for treating cancer |
WO2009155659A1 (en) * | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
EP2349984A1 (en) * | 2008-10-17 | 2011-08-03 | Merck & Co. | Combination therapy |
-
2013
- 2013-05-14 SG SG10201608469RA patent/SG10201608469RA/en unknown
- 2013-05-14 WO PCT/US2013/040877 patent/WO2013173283A1/en active Application Filing
- 2013-05-14 BR BR112014028420A patent/BR112014028420A2/pt not_active Application Discontinuation
- 2013-05-14 AU AU2013263043A patent/AU2013263043B2/en not_active Ceased
- 2013-05-14 JP JP2015512735A patent/JP6381523B2/ja not_active Expired - Fee Related
- 2013-05-14 NZ NZ700924A patent/NZ700924A/en not_active IP Right Cessation
- 2013-05-14 CN CN201380025377.6A patent/CN104349779A/zh active Pending
- 2013-05-14 EP EP13729120.9A patent/EP2849756A1/en not_active Withdrawn
- 2013-05-14 US US14/400,444 patent/US10213432B2/en active Active
- 2013-05-14 KR KR1020147031775A patent/KR20150009540A/ko not_active Application Discontinuation
- 2013-05-14 MX MX2014013904A patent/MX360892B/es active IP Right Grant
- 2013-05-14 RU RU2014150860A patent/RU2630975C2/ru not_active IP Right Cessation
- 2013-05-14 SG SG11201406550QA patent/SG11201406550QA/en unknown
- 2013-05-14 CA CA2872526A patent/CA2872526A1/en not_active Abandoned
-
2014
- 2014-10-13 ZA ZA2014/07406A patent/ZA201407406B/en unknown
- 2014-10-17 TN TN2014000433A patent/TN2014000433A1/fr unknown
- 2014-11-06 IL IL235567A patent/IL235567B/en not_active IP Right Cessation
- 2014-11-14 PH PH12014502547A patent/PH12014502547A1/en unknown
- 2014-11-14 CL CL2014003101A patent/CL2014003101A1/es unknown
-
2015
- 2015-03-25 HK HK15103031.8A patent/HK1202435A1/xx unknown
-
2018
- 2018-01-12 JP JP2018003680A patent/JP2018108998A/ja active Pending
- 2018-12-21 US US16/230,737 patent/US20190134052A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ700924A (en) | 2016-02-26 |
SG11201406550QA (en) | 2014-11-27 |
JP6381523B2 (ja) | 2018-08-29 |
WO2013173283A1 (en) | 2013-11-21 |
TN2014000433A1 (en) | 2016-03-30 |
US20150141426A1 (en) | 2015-05-21 |
EP2849756A1 (en) | 2015-03-25 |
JP2018108998A (ja) | 2018-07-12 |
ZA201407406B (en) | 2015-11-25 |
AU2013263043B2 (en) | 2016-06-16 |
SG10201608469RA (en) | 2016-11-29 |
BR112014028420A2 (pt) | 2017-09-19 |
HK1202435A1 (en) | 2015-10-02 |
MX2014013904A (es) | 2015-01-16 |
CL2014003101A1 (es) | 2015-02-27 |
IL235567A0 (en) | 2015-01-29 |
RU2630975C2 (ru) | 2017-09-15 |
CN104349779A (zh) | 2015-02-11 |
RU2014150860A (ru) | 2016-07-10 |
JP2015517523A (ja) | 2015-06-22 |
CA2872526A1 (en) | 2013-11-21 |
US20190134052A1 (en) | 2019-05-09 |
IL235567B (en) | 2019-08-29 |
MX360892B (es) | 2018-11-20 |
AU2013263043A1 (en) | 2014-10-30 |
PH12014502547A1 (en) | 2015-01-21 |
US10213432B2 (en) | 2019-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20150009540A (ko) | Pi-3 키나제 억제제에 대한 투여 요법 | |
WO2019067843A1 (en) | PYRAZOLO [3,4-B] PYRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHATASE SHP2 | |
JP6058009B2 (ja) | Pi3k−およびmek−阻害剤の相乗的な組合せ | |
KR20210132219A (ko) | 암의 치료를 위한 조합 요법 | |
JP2003525240A (ja) | 糖尿病性腎障害の処置のためのpdgf受容体チロシンキナーゼ阻害剤の使用 | |
WO2018060833A1 (en) | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib | |
US20210196696A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | |
JP2017214387A (ja) | 増殖性疾患の治療のためのhsp90阻害剤と組み合わせた2−カルボキサミドシクロアミノウレア誘導体 | |
US20220008409A1 (en) | Cancer combination therapy using quinoline carboxamide derivative | |
KR20180073674A (ko) | 포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법 | |
JP6212563B2 (ja) | ホスファチジルイノシトール3−キナーゼ阻害剤およびアロマターゼ阻害剤を含む組合せ医薬 | |
TW202342043A (zh) | 使用ptpn11抑制劑及egfr抑制劑之組合療法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |